Skip to content

Nasdaq · CIK 0002036042

SION Sionna Therapeutics, Inc.

Insider trading from SEC Form 4. Last filing 20 d ago. Close $4.90 on Oct 9, 2026, +9% from the 52-week low and -90% from the high.

Last 90 days

Net insider value
-$22M
more sold than bought
Buys
0
$0 by 0 insiders
Sells
1
$22M by 1 insider
Insiders on file
8
with a Form 4 at this company

Price and insider trades, last year

SIONOct 9, 2026 · close 4.90

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™

Signals

Open-market buys and sells at Sionna Therapeutics, Inc., scored.

ScoreInsiderValueHoldingsPrice contextFiled
50ModerateRa Capital Management, L.p.
director, owner
sell
$22M
3,448,811 shares
-50%-
53ModerateTpg Gp A, LLC
owner
buy
$20M
1,125,000 shares
+20%-
50ModerateAtlas Venture Fund XI, L.P.
owner
buy
$1.1M
60,000 shares
+8%-
58ModerateBruce Booth
director
buy
$1.1M
60,000 shares
+8%-
58ModerateRa Capital Management, L.p.
director, owner
buy
$20M
1,125,000 shares
+19%-

Transactions

The last 57 rows filed, every code.

DateInsiderTransactionSharesPriceValueHoldings afterFiled
Sep 17, 2026Ra Capital Management, L.p.
director, owner
SOpen-market sale
Common Stockindirect: See footnotes
-3,415,011$6.32$22M3,482,61220 d ago
Sep 17, 2026Ra Capital Management, L.p.
director, owner
SOpen-market sale
Common Stockindirect: See footnotes
-33,800$7.46$252k3,448,81220 d ago
Sep 17, 2026Michael Cloonan
President & CEO
AGrant or award
Common Stock
+109,025$0.00$0656,36823 d ago
Sep 17, 2026Jennifer Fitzpatrick
CLO and Head of Program Mgmt.
AGrant or award
Common Stock
+28,133$0.00$028,13323 d ago
Sep 17, 2026Charlotte McKee
CMO and Head of R&D
AGrant or award
Common Stock
+50,000$0.00$078,41523 d ago
Sep 17, 2026Elena Ridloff
CFO and CBO
AGrant or award
Common Stock
+47,269$0.00$085,80123 d ago
Sep 17, 2026Michael Cloonan
President & CEO
AGrant or award
Common Stock
+109,025$0.00$0765,39323 d ago
Sep 17, 2026Jennifer Fitzpatrick
CLO and Head of Program Mgmt.
AGrant or award
Common Stock
+28,132$0.00$056,26523 d ago
Sep 17, 2026Charlotte McKee
CMO and Head of R&D
AGrant or award
Common Stock
+50,000$0.00$0128,41523 d ago
Sep 17, 2026Elena Ridloff
CFO and CBO
AGrant or award
Common Stock
+47,268$0.00$0133,06923 d ago
Sep 17, 2026Michael Cloonan
President & CEO
AGrant or award
Non-Qualified Stock Option (right to buy)derivative
+436,100$0.00$0436,10023 d ago
Sep 17, 2026Jennifer Fitzpatrick
CLO and Head of Program Mgmt.
AGrant or award
Non-Qualified Stock Option (right to buy)derivative
+103,140$0.00$0103,14023 d ago
Sep 17, 2026Charlotte McKee
CMO and Head of R&D
AGrant or award
Non-Qualified Stock Option (right to buy)derivative
+155,700$0.00$0155,70023 d ago
Sep 17, 2026Elena Ridloff
CFO and CBO
AGrant or award
Non-Qualified Stock Option (right to buy)derivative
+165,440$0.00$0165,44023 d ago
Sep 17, 2026Charlotte McKee
CMO and Head of R&D
DDisposition to issuer
Non-Qualified Stock Option (right to buy)derivative
-155,700$0.00$0023 d ago
Sep 17, 2026Elena Ridloff
CFO and CBO
DDisposition to issuer
Non-Qualified Stock Option (right to buy)derivative
-165,440$0.00$0023 d ago
Sep 17, 2026Jennifer Fitzpatrick
CLO and Head of Program Mgmt.
DDisposition to issuer
Non-Qualified Stock Option (right to buy)derivative
-103,140$0.00$0023 d ago
Sep 17, 2026Michael Cloonan
President & CEO
DDisposition to issuer
Non-Qualified Stock Option (right to buy)derivative
-436,100$0.00$0023 d ago
Feb 10, 2025Tpg Gp A, LLC
owner
CConversion
Common Stockindirect: See Explanation of Responses
+4,875,547--5,559,962Feb 12, 2025
Feb 10, 2025Tpg Gp A, LLC
owner
POpen-market purchase
Common Stockindirect: See Explanation of Responses
+1,125,000$18.00$20M6,684,962Feb 12, 2025
Feb 10, 2025Tpg Gp A, LLC
owner
CConversion
Series Seed Preferred Stockderivativeindirect: See Explanation of Responses
-1,276,276--0Feb 12, 2025
Feb 10, 2025Tpg Gp A, LLC
owner
CConversion
Series A Preferred Stockderivativeindirect: See Explanation of Responses
-1,806,318--0Feb 12, 2025
Feb 10, 2025Tpg Gp A, LLC
owner
CConversion
Series B Preferred Stockderivativeindirect: See Explanation of Responses
-2,275,528--0Feb 12, 2025
Feb 10, 2025Tpg Gp A, LLC
owner
CConversion
Series C Preferred Stockderivativeindirect: See Explanation of Responses
-1,765,541--0Feb 12, 2025
Feb 6, 2025Michael Cloonan
President & CEO
AGrant or award
Stock Option (Right to Buy)derivative
+450,252$0.00$0450,252Feb 10, 2025
Feb 10, 2025Ra Capital Management, L.p.
director, owner
CConversion
Common Stockindirect: See footnotes
+5,021,990--5,900,779Feb 10, 2025
Feb 10, 2025Atlas Venture Fund XI, L.P.
owner
CConversion
Common Stock
+2,886,293--2,886,293Feb 10, 2025
Feb 10, 2025Bruce Booth
director
CConversion
Common Stockindirect: By Atlas Venture Fund XI, L.P.
+2,886,293--2,886,293Feb 10, 2025
Feb 10, 2025Ra Capital Management, L.p.
director, owner
CConversion
Common Stockindirect: See footnotes
+527,444--869,651Feb 10, 2025
Feb 10, 2025Atlas Venture Fund XI, L.P.
owner
CConversion
Common Stockindirect: By Atlas Venture Opportunity Fund II, L.P.
+747,727--747,727Feb 10, 2025
Feb 10, 2025Bruce Booth
director
CConversion
Common Stockindirect: By Atlas Venture Opportunity Fund II, L.P.
+747,727--747,727Feb 10, 2025
Feb 10, 2025Ra Capital Management, L.p.
director, owner
CConversion
Common Stockindirect: See footnotes
+2,222,084--2,222,084Feb 10, 2025
Feb 10, 2025Bruce Booth
director
POpen-market purchase
Common Stockindirect: By Atlas Venture Opportunity Fund II, L.P.
+60,000$18.00$1.1M807,727Feb 10, 2025
Feb 10, 2025Atlas Venture Fund XI, L.P.
owner
POpen-market purchase
Common Stockindirect: By Atlas Venture Opportunity Fund II, L.P.
+60,000$18.00$1.1M807,727Feb 10, 2025
Feb 10, 2025Ra Capital Management, L.p.
director, owner
CConversion
Common Stockindirect: See footnotes
+179,975--327,808Feb 10, 2025
Feb 10, 2025Bruce Booth
director
CConversion
Series Seed convertible preferred stockderivativeindirect: By Atlas Venture Fund XI, L.P.
-1,051,051$0.00$00Feb 10, 2025
Feb 10, 2025Atlas Venture Fund XI, L.P.
owner
CConversion
Series Seed convertible preferred stockderivative
-1,051,051$0.00$00Feb 10, 2025
Feb 10, 2025Atlas Venture Fund XI, L.P.
owner
CConversion
Series A convertible preferred stockderivative
-1,806,317$0.00$00Feb 10, 2025
Feb 10, 2025Ra Capital Management, L.p.
director, owner
POpen-market purchase
Common Stockindirect: See footnotes
+1,022,586$18.00$18M6,923,365Feb 10, 2025
Feb 10, 2025Bruce Booth
director
CConversion
Series A convertible preferred stockderivativeindirect: By Atlas Venture Fund XI, L.P.
-1,806,317$0.00$00Feb 10, 2025
Feb 10, 2025Atlas Venture Fund XI, L.P.
owner
CConversion
Series B convertible preferred stockderivative
-1,298,332$0.00$00Feb 10, 2025
Feb 10, 2025Bruce Booth
director
CConversion
Series B convertible preferred stockderivativeindirect: By Atlas Venture Fund XI, L.P.
-1,298,332$0.00$00Feb 10, 2025
Feb 10, 2025Ra Capital Management, L.p.
director, owner
POpen-market purchase
Common Stockindirect: See footnotes
+102,414$18.00$1.8M2,324,498Feb 10, 2025
Feb 10, 2025Bruce Booth
director
CConversion
Series C convertible preferred stockderivativeindirect: By Atlas Venture Fund XI, L.P.
-61,463$0.00$00Feb 10, 2025
Feb 10, 2025Ra Capital Management, L.p.
director, owner
CConversion
Series Seed Preferred Stockderivativeindirect: See footnotes
-819,153$0.00$00Feb 10, 2025
Feb 10, 2025Atlas Venture Fund XI, L.P.
owner
CConversion
Series C convertible preferred stockderivative
-61,463$0.00$00Feb 10, 2025
Feb 10, 2025Bruce Booth
director
CConversion
Series C convertible preferred stockderivativeindirect: By Atlas Venture Opportunity Fund II, L.P.
-1,092,504$0.00$00Feb 10, 2025
Feb 10, 2025Atlas Venture Fund XI, L.P.
owner
CConversion
Series C convertible preferred stockderivativeindirect: By Atlas Venture Opportunity Fund II, L.P.
-1,092,504$0.00$00Feb 10, 2025
Feb 10, 2025Ra Capital Management, L.p.
director, owner
CConversion
Series Seed Preferred Stockderivativeindirect: See footnotes
-319,069$0.00$00Feb 10, 2025
Feb 10, 2025Ra Capital Management, L.p.
director, owner
CConversion
Series Seed Preferred Stockderivativeindirect: See footnotes
-138,054$0.00$00Feb 10, 2025
Feb 10, 2025Ra Capital Management, L.p.
director, owner
CConversion
Series A Preferred Stockderivativeindirect: See footnotes
-1,229,830$0.00$00Feb 10, 2025
Feb 10, 2025Ra Capital Management, L.p.
director, owner
CConversion
Series A Preferred Stockderivativeindirect: See footnotes
-451,580$0.00$00Feb 10, 2025
Feb 10, 2025Ra Capital Management, L.p.
director, owner
CConversion
Series A Preferred Stockderivativeindirect: See footnotes
-124,908$0.00$00Feb 10, 2025
Feb 10, 2025Ra Capital Management, L.p.
director, owner
CConversion
Series B Preferred Stockderivativeindirect: See footnotes
-923,773$0.00$00Feb 10, 2025
Feb 10, 2025Ra Capital Management, L.p.
director, owner
CConversion
Series B Preferred Stockderivativeindirect: See footnotes
-2,155,469$0.00$00Feb 10, 2025
Feb 10, 2025Ra Capital Management, L.p.
director, owner
CConversion
Series C Preferred Stockderivativeindirect: See footnotes
-4,364,874$0.00$00Feb 10, 2025
Feb 10, 2025Ra Capital Management, L.p.
director, owner
CConversion
Series C Preferred Stockderivativeindirect: See footnotes
-1,091,219$0.00$00Feb 10, 2025

Insiders

Everyone who has filed a Form 4 here.

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

SION insider trading: Sionna Therapeutics, Inc. | InsiderTell